KRAS mutations are associated with solid growth pattern and tumor-infiltrating leukocytes in lung adenocarcinoma

Tumor Islands in Resected Early-stage Lung Adenocarcinomas are Associated With Unique Clinicopathologic and Molecular Characteristics and Worse Prognosis

(2012) Maristela L. Onozato et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

KRAS Mutation in Patients with Lung Cancer: A Predictor for Poor Prognosis but Not for EGFR-TKIs or Chemotherapy

(2012) Ji-lin Guan et al.   ANNALS OF SURGICAL ONCOLOGY

Molecular Epidemiology of EGFR and KRAS Mutations in 3,026 Lung Adenocarcinomas: Higher Susceptibility of Women to Smoking-Related KRAS-Mutant Cancers

(2012) S. Dogan et al.   CLINICAL CANCER RESEARCH

Clarifying the Spectrum of Driver Oncogene Mutations in Biomarker-Verified Squamous Carcinoma of Lung: Lack of EGFR/KRAS and Presence of PIK3CA/AKT1 Mutations

(2012) N. Rekhtman et al.   CLINICAL CANCER RESEARCH

Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study

(2012) Pasi A Jänne et al.   LANCET ONCOLOGY

Reproducibility of histopathological subtypes and invasion in pulmonary adenocarcinoma. An international interobserver study

(2012) Erik Thunnissen et al.   MODERN PATHOLOGY

Distinct profile of driver mutations and clinical features in immunomarker-defined subsets of pulmonary large-cell carcinoma

(2012) Natasha Rekhtman et al.   MODERN PATHOLOGY

Molecular pathology of lung cancer: key to personalized medicine

(2012) Liang Cheng et al.   MODERN PATHOLOGY

Chipping away at the lung cancer genome

(2012) William Pao et al.   NATURE MEDICINE

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

(2012) Julie R. Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

The split nature of tumor-infiltrating leukocytes

(2012) Telma Lança et al.   OncoImmunology

Comprehensive Histologic Analysis of ALK-Rearranged Lung Carcinomas

(2011) Akihiko Yoshida et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Clinicopathological features of lung adenocarcinoma with KRAS mutations

(2011) Seiichi Kakegawa et al.   CANCER

Prognostic Immune Markers in Non–Small Cell Lung Cancer

(2011) Kei Suzuki et al.   CLINICAL CANCER RESEARCH

Cytomorphologic features of advanced lung adenocarcinomas tested for EGFR and KRAS mutations: A retrospective review of 50 cases

(2011) Jonathan D. Marotti et al.   DIAGNOSTIC CYTOPATHOLOGY

Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma

(2011) N. Girard et al.   EUROPEAN RESPIRATORY JOURNAL

Detection of KRAS and BRAF Mutations in Colorectal Carcinoma

(2011) Maria Arcila et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Insulin-like growth factor-1 receptor inhibition overcomes gefitinib resistance in mucinous lung adenocarcinoma

(2011) Amandine Hurbin et al.   JOURNAL OF PATHOLOGY

Increased Levels of Tumor-Infiltrating Lymphocytes are Associated with Improved Recurrence-Free Survival in Stage 1A Non-Small-Cell Lung Cancer

(2011) Zachary D. Horne et al.   JOURNAL OF SURGICAL RESEARCH

International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma

(2011) William D. Travis et al.   Journal of Thoracic Oncology

Worse Disease-Free Survival in Never-Smokers with ALK+ Lung Adenocarcinoma

(2011) Ping Yang et al.   Journal of Thoracic Oncology

Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases

(2011) Akihiko Yoshizawa et al.   MODERN PATHOLOGY

Immunohistochemical algorithm for differentiation of lung adenocarcinoma and squamous cell carcinoma based on large series of whole-tissue sections with validation in small specimens

(2011) Natasha Rekhtman et al.   MODERN PATHOLOGY

Epithelial Tissues Have Varying Degrees of Susceptibility to KrasG12D-Initiated Tumorigenesis in a Mouse Model

(2011) Kevin C. Ray et al.   PLoS One

A Grading System of Lung Adenocarcinomas Based on Histologic Pattern is Predictive of Disease Recurrence in Stage I Tumors

(2010) Gabriel Sica et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation

(2010) Kenichi Suda et al.   CANCER AND METASTASIS REVIEWS

Tumor-Infiltrating Foxp3+ Regulatory T Cells are Correlated with Cyclooxygenase-2 Expression and are Associated with Recurrence in Resected Non-small Cell Lung Cancer

(2010) Katsuhiko Shimizu et al.   Journal of Thoracic Oncology

EGFR and KRAS status of primary sarcomatoid carcinomas of the lung: Implications for anti-EGFR treatment of a rare lung malignancy

(2009) Antoine Italiano et al.   INTERNATIONAL JOURNAL OF CANCER

Prognostic value of KRAS mutations and Ki-67 expression in stage I lung adenocarcinomas

(2009) Tetsukan Woo et al.   LUNG CANCER

Clinicopathological predictors of EGFR/KRAS mutational status in primary lung adenocarcinomas

(2009) Sanja Dacic et al.   MODERN PATHOLOGY

Are RAS mutations predictive markers of resistance to standard chemotherapy?

(2009) Yohann Loriot et al.   Nature Reviews Clinical Oncology

Lung Adenocarcinoma: Modification of the 2004 WHO Mixed Subtype to Include the Major Histologic Subtype Suggests Correlations Between Papillary and Micropapillary Adenocarcinoma Subtypes, EGFR Mutations and Gene Expression Analysis

(2008) Noriko Motoi et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

KRAS Mutations

(2008) Gregory J. Riely et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Prognostic and Therapeutic Implications of EGFR and KRAS Mutations in Resected Lung Adenocarcinoma

(2008) Jenifer L. Marks et al.   Journal of Thoracic Oncology